Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-03654764 +/- Allegra in Allergic Rhinitis
NCT01033396Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2010
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-03654764 in allergic rhinitis (AR) (4 arms), sponsored by Pfizer. Primary endpoints: Congestion scores at 6 hours and Other allergic rhinitis symptoms at 6 hours. Started Jan 2010; status: completed.
02
Drugs
PF-03654764
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT01033396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01033396.